Xeris Biopharma Holdings (XERS) said Friday it now expects 2024 revenue of $203 million, compared with its prior guidance of between $198 million and $202 million.
Analysts polled by FactSet expect $199.7 million.
The company said it expects Q4 revenue of $60 million.
Analysts surveyed by FactSet expect $56.7 million.
Price: 3.38, Change: +0.02, Percent Change: +0.60
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。